bimagrumab plus semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment Bimagrumab preserves lean mass and

In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape

We are closely discussing it with the health authorities to make Mounjaro reimbursable, said Lee Hyuk, director of Eli Lilly Korea's Diabetes Business Division, who is responsible for marketing Mounjaro

Longer-term effects on energy, recovery, and overall wellbeing develop across the cycle and in the weeks following

Injectable glutathione may sound appealing as a quick fix for skin lightening or general glow but scientific evidence does not support its effectiveness , and risks are real and significant

If you have type 2 diabetes and take insulin or sulfonylureas, dose reductions may be needed to prevent hypoglycaemia

Statements Author contributions HS: Writing original draft